Metronomic therapy: It makes sense and is patient friendly

Journal of Pediatric Hematology/Oncology

Volumn 27, Issue 11, 2005, Pages 571-572

  Kamen, Barton A ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; ANTINEOPLASTIC AGENT; CELECOXIB; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERYTHROPOIETIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; PREDNISONE; STEROID; THALIDOMIDE; VINCA ALKALOID; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIANGIOGENIC ACTIVITY; ARTHRITIS; CANCER CHEMOTHERAPY; DNA DAMAGE; DOSE RESPONSE; DRUG POTENCY; DRUG SAFETY; EDITORIAL; GRAFT VERSUS HOST REACTION; HUMAN; LETHAL DOSE; LOW DRUG DOSE; LYMPHOMA; MAXIMUM TOLERATED DOSE; MUTAGENIC ACTIVITY; NEPHROBLASTOMA; ORGAN INJURY; PRIORITY JOURNAL; RECURRENT CANCER; RHABDOMYOSARCOMA; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DISEASE PROGRESSION; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 28144461113     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/01.mph.0000192148.90120.15     Document Type: Editorial

References (14)

1. Kieran MW, Turner C, Rubin J, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol. 2005;11:573-581.
2. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423-436.
3. Bocci G, Tuccori M, Emmenegger U, et al. Del Tacca M Cyclophosphamide- methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmaco-economic evaluation. Ann Oncol. 2005;6:1243-1252.
4. Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002;13:73-80.
5. Glode LM, Barqawi A, Crighton F, et al. Metronomic therapy with cyclophosphadmide and dexamethasone for prostate cancer. Cancer. 2003;98:1643-1648.
6. Teicher BA, Solomayor EA, Huang ZD. Antiangiogenic agents potentiate cytoxic cancer therapies against primary and metastatic disease. Cancer Res. 1992;52:6702-6704.
7. Weitman SD, Glatstein E, Kamen BA. Back to the Basics: The importance of concentration x time in oncology. J Clin Onc. 1993;11:820-821.
8. Kamen BA, Rubin E, Glatstein E, et al. High time chemotherapy or high time for low dose. J Clin Oncol. 2000;18:2935-2937.
9. Frost P, Kamen BA. The Bullseye of cancer therapy: a moving target. Current Opinions in Pharmacology. 2003;3:335-337.
10. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
11. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105:1045-1047.
12. Fornier M, Norton L. Dose-dense adjuvant chemotherapy for primary breast cancer. Breast Cancer Res. 2005;7:64-69.
13. Kamen BA, Glod J. What is the price of an erythrocyte and neutrophil? J Pediatr Hematol Oncol. 2004;26:699-700.
14. Shaked Y, Emmenegger U, Francia G, et al. Low-dose Metronomic Combined with Intermittent Bolus-dose Cyclophosphamide Is an Effective Long-term Chemotherapy Treatment Strategy. Cancer Res. 2005;15:7045-7051.